Protagonist Therapeutics (PTGX)

Common Shares

Sell: $43.00|Buy: $108.04|Change: 1.71 (-1.62%)

Open

$103.59

Previous close

$105.44

Trade high

$104.53

Volume

417,822

Year high

$107.84

Year low

$41.285

Dividend yield

–

Market capitalisation

$6.62 bn

P/E ratio

133.92

ISIN

US74366E1029

This share can be held in a Dealing account Stocks and shares ISA Lifetime ISA JISA SIPP

Share price

Performance 16/04/2026

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
Protagonist Therapeutics	- 1.62
More...

Company profile

Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.

Sector

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.